Stay updated on Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.

Latest updates to the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the Record History page, indicating a routine site release rather than a content change to the study record.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedFooter revision label updated from v3.5.2 to v3.5.3, signaling a new site build rather than a modification to the study record.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedA new revision entry v3.5.2 has been added to the record history, replacing the older v3.5.0 entry.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision history updated to add v3.5.0 and remove v3.4.3 from the record history. This is an administrative update to the record-keeping and does not change the study content.SummaryDifference0.1%

- Check67 days agoChange DetectedVersion 3.4.3 adds Contacts/Locations, Study Design, Study Status, and Recruitment Status. It also updates the recruitment status to Active, not recruiting on 2026-03-05, replacing the previous Recruiting status.SummaryDifference1%

- Check96 days agoChange DetectedRevision: v3.4.2 added to the Record History; removed a government funding lapse notice and Revision: v3.4.1.SummaryDifference0.9%

Stay in the know with updates to Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.